Moleculin Biotech, Inc. Business Acquisition, Pro Forma Net Income (Loss)
Moleculin Biotech, Inc. (MBRX) reported Business Acquisition, Pro Forma Net Income (Loss) of -$3.96 million for the 12-month period ending 2016-12-31, per its 10-K filed 2018-03-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2018-03-28
- Moleculin Biotech, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2016-12-31 was -$1.42M, a 331.19% decline year-over-year.
- Moleculin Biotech, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2016-09-30 was -$1.43M.
- Moleculin Biotech, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2016-06-30 was -$709.83K.
- Moleculin Biotech, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2016-03-31 was -$446.41K.
- Moleculin Biotech, Inc. business acquisition, pro forma net income (loss) for fiscal 2016 was -$3.96M.
- Moleculin Biotech, Inc. business acquisition, pro forma net income (loss) for fiscal 2015 was -$164.13K.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 3 month as first filed | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 6 month as first filed | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2016-12-31 | -$1.42M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-28 | -$2.86M derived: sum of 2 quarters · filed 2018-03-28 | -$3.57M derived: sum of 3 quarters · filed 2018-03-28 | -$3.96M 10-K · filed 2018-03-28 | -$3.96M 10-K · filed 2017-04-03 | ||
| 2016-09-30 | -$1.43M 10-Q · filed 2016-11-21 | -$2.14M derived: sum of 2 quarters · filed 2016-11-21 | -$2.54M 10-Q · filed 2016-11-21 | -$1.97M derived: sum of 4 quarters · filed 2017-04-03 | |||
| 2016-06-30 | -$709.83K 10-Q · filed 2016-11-21 | -$1.04M 10-Q · filed 2016-08-15 | -$1.16M 10-Q · filed 2016-11-21 | -$1.56M 10-Q · filed 2016-08-15 | -$540.58K derived: sum of 3 quarters · filed 2017-04-03 | -$837.71K derived: sum of 4 quarters · filed 2017-04-03 | |
| 2016-03-31 | -$446.41K 10-Q · filed 2016-06-16 | $169.25K derived: sum of 2 quarters · filed 2017-04-03 | -$127.88K derived: sum of 3 quarters · filed 2017-04-03 | ||||
| 2015-12-31 | $615.65K derived: 10-K 12 month − 10-Q 9 month · filed 2017-04-03 | $318.52K derived: sum of 2 quarters · filed 2017-04-03 | -$164.13K 10-K · filed 2017-04-03 | ||||
| 2015-09-30 | -$297.13K 10-Q · filed 2016-11-21 | -$779.78K 10-Q · filed 2016-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |